BioSig Technologies

200 articles with BioSig Technologies

• BioSig CEO Kenneth L. Londoner to Present at the Sidoti Winter 2021 Investor Conference

  1/6/2021

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the Sidoti Winter 2021 Investor Conference on Wednesda

• BioSig Achieves First Commercial Sale of Three PURE EP SystemsSale Marks Milestone for Company's Commercial expansion at leading Center of Excellence

  12/11/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the purchase of three PURE EP™ Systems by St. David’s HealthCare of Austin, Texas. St. David’s Medical Center, an HCA Healthcare owned hospital, has been recognized with a Malcolm B

• BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference

  12/10/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the 13 th Annual LD Micro Main Event Conference on Mo

• BioSig to Highlight PURE EP™ System at the Benzinga Global Small Cap Conference

  12/3/2020

  The company's PURE EP™ System is currently installed in six medical centers across the country Evaluation installations are growing and provide a strong foundation for commercial efforts in 2021 BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac s

• BioSig’s PURE EP System to Support Live Patient Cases during EPLive 2020Company’s flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020

  11/30/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its flagship technology would be featured in several live cases broadcast during EPLive 2020, the fifth international symposium on complex arrhythmias. EPLive is an intensive,

• BioSig to Host Business Update Conference Call on November 18, 2020

  11/12/2020

  BioSig Technologies, Inc., a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that it would host a call on November 18, 2020, at 4:15 PM ET.

• BioSig Announces Completion of PURE EP™ System Installation at New Medical CenterFirst Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center

  10/29/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EP™ System and started conducting patient cases at Deborah Heart and Lung Center in Browns Mills, New Jersey. PURE EP™ System evaluation a

• BioSig Issues October 2020 Shareholder Update Letter

  10/28/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued an October 2020 Letter to Shareholders

• ViralClear halts its Phase 2 Hospitalized COVID-19 Trial

  10/26/2020

  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), announced the halting of its signal finding Phase 2 trial, “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination with Intravenous Remdesivir in Adult Patients with Advanced Coronavirus Disease 2019 (COVID-19)”.

• ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution

  9/22/2020

  Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices Added 2 new Principal Investigators for the ongoing Phase 2 trial expanding the total number of locations to 10 Contract Manufacturing Organization (CMO) appointed to manufacture Phase 3 supplies of merimepodib oral solution Me

• Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

  9/21/2020

  BioSig Technologies, Inc.’s subsidiary, ViralClear Pharmaceuticals, Inc., announced that it will host a call and webcast to discuss its Phase 2 clinical trial.

• BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

  9/15/2020

  Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

• Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

  9/14/2020

  BioSig Technologies, Inc. announced it will host a call and webcast to discuss the results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study. The data was generated during atrial fibrillation ablation procedures conducted at St. David’s Medical Center, Austin, Texas.

• BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

  9/14/2020

  Novel algorithm can successfully reconstruct ECG lead placements The method may improve the automated classification of patient conditions and unlock new applications of clinical value BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac

• BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

  9/2/2020

  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it will host a call to discuss the results from the

• BioSig to Present at The LD 500 Virtual Conference

  8/25/2020

  BioSig Technologies, Inc. (NASDAQ:BSGM), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will be presenting at the 12 th Annual LD 500 Conference on Wednesday, September 2, 2020 at 11:40 AM ET.

• BioSig Technologies to Present at The LD 500 Virtual Conference

  8/25/2020

  BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will be presenting at the 12th Annual LD 500 Conference on Wednesday, September 2, 2020, at 11:40 AM ET.  Kenneth L. Londoner, Chairman and CEO of BioSig Technolo

• ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board

  8/5/2020

  BioSig Technologies, Inc.’s subsidiary, ViralClear Pharmaceuticals, Inc., announced the addition of Dr. Michael J. Sofia to its Scientific Advisory Board.

• BioSig Installs PURE EP(tm) System at Massachusetts General HospitalPatient cases are set to commence in August

  8/4/2020

  BioSig Technologies, Inc., a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the Company installed its PURE EP System at Massachusetts General Hospital as part of an expanding clinical study.

• BioSig Awarded CAGE Code by the Systems for Award Management (SAM)Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government

  8/3/2020

  BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been awarded its Commercial and Government Entity (CAGE)